# US 2025/0382389 A2 · Methods and compositions for treating staphylococcal infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0382389 A2
- Document ID: US20250382389A2
- Status: Published application
- Kind: A2
- Application number: 17/753,692
- Filed: 2020-09-11
- Published: 2025-12-18
- Earliest claimed: 2019-09-13
- Assignees: The University of Chicago
- Applicants: The University of Chicago
- Inventors: Dominique M. MISSIAKAS; Olaf SCHNEEWIND; Xinhai CHEN
- Web page: https://patentgrep.com/patent/US20250382389A2

## CPC

- C07K 16/1271: Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
- C07K 16/464: {Igs containing CDR-residues from one specie grafted between FR-residues from another}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The current disclosure provides novel compositions for treating bacterial infections. Accordingly, aspects of the disclosure relate to an engineered antibody comprising: LCDR1, LCDR2, and LCDR3 of the light chain variable region of the 3F6 antibody and HCDR1, HCDR2, and HCDR3 of the heavy chain variable region of the 3F6 antibody. Also provided are compositions comprising the antibodies and nucleic acids encoding either the heavy chain or light chain (or both) of the antibodies. Other aspects relate to host cells comprising the antibodies and/or nucleic acids of the disclosure. Further aspects relate to a method of preventing or treating staphylococcal infection comprising the step of administering the antibody of the disclosure to a subject in need thereof. Yet further aspects relate to a method of making the antibody comprising expressing the nucleic acid(s) of the disclosure in a cell and isolating the expressed protein.

## Claims

### Claim 1

An engineered antibody comprising a light chain and heavy chain variable region comprising: LCDR1, LCDR2, and LCDR3 of the light chain variable region of the 3F6 antibody and HCDR1, HCDR2, and HCDR3 of the heavy chain variable region of the 3F6 antibody and wherein the antibody comprises an Fc region comprising at least one glycosylation-modified amino acid(s).

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the antibody is humanized.

### Claim 3

A humanized 3F6 antibody comprising a Fc region comprising at least one glycosylation-modified amino acid(s).

### Claim 4 (depends on 1, 2, 3)

The antibody of any one of claims 1-3, wherein the HCDR1, HCDR2, and HCDR3 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NOS:2, 3, and 4, respectively and wherein the LCDR1, LCDR2, and LCDR3 comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NOS:5, 6, and 7, respectively.

### Claim 5 (depends on 4)

The antibody of claim 4, wherein the HCDR1, HCDR2, and HCDR3 comprises the amino acid sequence of SEQ ID NOS:2, 3, and 4, respectively and wherein the LCDR1, LCDR2, and LCDR3 comprises an amino acid sequence of SEQ ID NOS:5, 6, and 7, respectively.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The antibody of any one of claims 1-5, wherein the antibody comprises fragment crystallizable region gamma (Fcγ).

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The antibody of any one of claims 1-6, wherein the Fc region of the antibody comprises one or more substitutions and wherein the one or more substitutions comprise S254A, Q311E, L432S, N434P and/or H435R.

### Claim 8 (depends on 7)

The antibody of claim 7, wherein the Fc region of the antibody comprises S254A, Q311E, L432S and N434P substitutions.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The antibody of any one of claims 1-8, wherein the antibody has at least one, at least two, at least 3, or at least 4 substitutions at one or more amino acids at positions 226-447 of the Fc region of the antibody.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The antibody any one of claim 1-9, wherein the Fc region of the antibody comprises one or more substitutions and wherein the one or more substitutions comprise T256D, N286D, T307R, T307Q, Q311V, A378V, and combinations thereof.

### Claim 11 (depends on 9, 10)

The antibody of claim 9 or 10, wherein the antibody is capable of increasing OPK activity in a subject, as compared to tefibazumab.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The antibody of any one of claims 1-11, wherein the glycosylation-modified amino acid comprises a galactosylated amino acid.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The antibody of any one of claims 1-12, wherein the antibody is galactosylated at Asn297.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The antibody of any one of claims 1-13, wherein the antibody is afucosylated.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The antibody of any one of claims 1-13, wherein the antibody is afucosylated at Asn297.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The antibody of any one of claims 1-15, wherein the antibody is de-sialylated.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The antibody of any one of claims 1-16, wherein the antibody is de-sialylated at Asn297.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The antibody of any one of claims 1-17, wherein the antibody is further defined as having a modification structure of G2S2F, G2F, G1F, G2 or G1.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A nucleic acid encoding a heavy chain and/or light chain of an antibody of any one of claims 1-18.

### Claim 20 (depends on 19)

A host cell comprising a nucleic acid of claim 19.

### Claim 21 (depends on 19)

A method of making the antibody comprising expressing the nucleic acid(s) of claim 19 in a cell and isolating the expressed protein.

### Claim 22 (depends on 21)

The method of claim 21, wherein the cell comprises expression of a heterologous glycosyltransferase.

### Claim 23 (depends on 22)

The method of claim 22, wherein the glycosyltransferase is modified.

### Claim 24 (depends on 21, 22, 23)

The method of any one of claims 21-23, wherein the cell is modified to reduce or eliminate expression of one or more fucosylation and/or sialyation enzymes.

### Claim 25 (depends on 24)

The method of claim 24, wherein the cell is modified to reduce or eliminate expression of Fut8 and/or 23STGal4/6.

### Claim 26 (depends on 21, 22)

The method of claim 21 or 22, wherein the cell comprises a mammalian cell.

### Claim 27 (depends on 21, 22)

The method of claim 21 or 22, wherein the cell comprises a human cell.

### Claim 28 (depends on 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 21-27, wherein the cell comprises endogenous glycosyltransferase activity.

### Claim 29 (depends on 21, 22, 23, 24, 25, 26)

The method of any one of claims 21-26, wherein the cell comprises a CHO cell.

### Claim 30 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 21-29, wherein the method comprises culturing the cell in media supplemented with galactose alone or galactose in combination with manganese chloride and/or uridine

### Claim 31 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 21-30, wherein the method comprises culturing the cell in afucosylated-enrichment medium.

### Claim 32 (depends on 31)

The method of claim 31, wherein the afucosylated-enrichment medium comprises kifunensine.

### Claim 33 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 21-32, wherein the method comprises culturing the cell in de-sialylation-enrichment medium.

### Claim 34 (depends on 30)

The method of claim 30, wherein the de-sialylation-enrichment medium comprises neuraminidase.

### Claim 35 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 21-34, wherein the method comprises culturing the cell in media supplemented with N-acetylmannosamine (ManNAc) and/or butyrated ManNAc.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method of preventing or treating staphylococcal infection or colonization comprising the step of administering the antibody of any one of claims 1-18 to a subject in need thereof.

### Claim 37 (depends on 34)

The method of claim 34, wherein treating or preventing comprises one or more of promoting S. aureus decolonization, preventing invasive MRSA disease, and improving the outcome of MRSA bloodstream infections in the subject.

### Claim 38 (depends on 36, 37)

The method of any one of claims 36-37, wherein the staphylococcal infection or colonization comprises infection or colonization of a Staphylococcus bacterium and wherein the bacterium comprises S. aureus bacterium.

### Claim 39 (depends on 38)

The method of claim 38, wherein the Staphylococcus bacterium is resistant to one or more treatments.

### Claim 40 (depends on 39)

The method of claim 39, wherein the bacterium is methicillin resistant.

### Claim 41 (depends on 36, 37, 38, 39, 40)

The method of any of claims 36-40, wherein the subject does not exhibit any signs of toxicity from the isolated polypeptide or composition.

### Claim 42 (depends on 41)

The method of claim 41, wherein the subject does not exhibit any signs of anaphylactic shock from the isolated polypeptide or composition.

### Claim 43 (depends on 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 36-42, wherein the subject is a human.

### Claim 44 (depends on 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 36-43, wherein the antibody is administered intravenously.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A use of the antibody of any of claims 1-18 in the manufacture of a medicament for the treatment or prevention of staphylococcal infection.
